Chemical inactivation of recombinant vaccinia viruses and the effects on antigenicity and immunogenicity of recombinant simian immunodeficiency virus envelope glycoproteins

By Hulskotte E.G.J.   Dings M.E.M.   Norley S.G.   Osterhaus A.D.M.E.  

Vaccine, Vol. 15, Iss. 17, 1997-12 ,pp. : 1839-1845

Elsevier

Access to resources Recommend Favorite

Construction and characterization of a Salmonella typhi-based human immunodeficiency virus type 1 vector vaccine

By Fouts T.R.   Lewis G.K.   Hone D.M.  

Vaccine, Vol. 13, Iss. 6, 1995-04 ,pp. : 561-569

Elsevier

Access to resources Recommend Favorite

Acellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection

By de Martino M.   Podda A.   Galli L.   Sinangil F.   Mannelli F.   Rossi M.E.   Vierucci A.  

Vaccine, Vol. 15, Iss. 11, 1997-08 ,pp. : 1235-1238

Elsevier

Access to resources Recommend Favorite

Human immunodeficiency virus-1 principal neutralizing domain peptide-toxin A conjugate vaccine

By Cryz S.J.   Goldstein H.   Pettoello-Mantovani M.   Kim A.   Furer E.   Que J.U.   Hasler T.   Rubinstein A.  

Vaccine, Vol. 13, Iss. 1, 1995-01 ,pp. : 67-71

Elsevier

Access to resources Recommend Favorite

The simian immunodeficiency virus transmembrane protein is poorly immunogenic in inactivated virus vaccine

By Cranage M.P.   McBride B.W.   Rud E.W.  

Vaccine, Vol. 13, Iss. 10, 1995-07 ,pp. : 895-900

Elsevier

Access to resources Recommend Favorite